دورية أكاديمية
Pharmacological management of osteogenesis
| العنوان: | Pharmacological management of osteogenesis |
|---|---|
| المؤلفون: | Valeria Nardone, Federica D'Asta, Maria Luisa Brandi |
| المصدر: | Clinics, Vol 69, Iss 6, Pp 438-446 (2014) |
| بيانات النشر: | Elsevier España |
| سنة النشر: | 2014 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Antiresorptive Drugs, Bone Formation, Osteoblasts, Osteogenesis, RANKL Inhibitors, Medicine (General), R5-920 |
| الوصف: | Osteogenesis and bone remodeling are complex biological processes that are essential for the formation of new bone tissue and its correct functioning. When the balance between bone resorption and formation is disrupted, bone diseases and disorders such as Paget's disease, fibrous dysplasia, osteoporosis and fragility fractures may result. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss that are based on the inhibition of bone resorption by osteoclasts or the stimulation of bone formation by osteoblasts. Bisphosphonates, antiresorptive agents that reduce bone resorption, are usually recommended as first-line therapy in women with postmenopausal osteoporosis. Numerous studies have shown that bisphosphonates are able to significantly reduce the risk of femoral and vertebral fractures. Other antiresorptive agents indicated for the treatment of osteoporosis include selective estrogen receptor modulators, such as raloxifene. Denosumab, a human monoclonal antibody, is another antiresorptive agent that has been approved in Europe and the USA. This agent blocks the RANK/RANKL/OPG system, which is responsible for osteoclastic activation, thus reducing bone resorption. Other approved agents include bone anabolic agents, such as teriparatide, a recombinant parathyroid hormone that improves bone microarchitecture and strength, and strontium ranelate, considered to be a dual-action drug that acts by both osteoclastic inhibition and osteoblastic stimulation. Currently, anti-catabolic drugs that act through the Wnt-β catenin signaling pathway, serving as Dickkopf-related protein 1 inhibitors and sclerostin antagonists, are also in development. This concise review provides an overview of the drugs most commonly used for the control of osteogenesis in bone diseases. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1980-5322 |
| العلاقة: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322014000600438&lng=en&tlng=enTest; https://doaj.org/toc/1980-5322Test; https://doaj.org/article/d707fe713721439aaaa09fe378927df0Test |
| DOI: | 10.6061/clinics/2014(06)12 |
| الإتاحة: | https://doi.org/10.6061/clinics/2014Test(06)12 https://doaj.org/article/d707fe713721439aaaa09fe378927df0Test |
| رقم الانضمام: | edsbas.A19FC544 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 19805322 |
|---|---|
| DOI: | 10.6061/clinics/2014(06)12 |